Form 4: PAVmed Inc. Director Timothy Baxter Acquires Shares

PAVmed Inc. reports that Director Timothy Baxter acquired 13,930 shares of common stock on April 2, 2026, as part of a restricted stock grant.

Summary

• Timothy E. Baxter, a Director of PAVmed Inc., acquired 13,930 shares of common stock on April 2, 2026.
• The acquisition was made through a restricted stock grant under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
• These shares have a single vesting date of May 20, 2029, and are subject to forfeiture if the service period is not completed.
• The reported transaction has a value of $0, indicating it was a grant rather than a purchase.
• Following this transaction, Timothy E. Baxter beneficially owns 21,097 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It represents a standard insider stock grant for compensation purposes and does not provide new financial information or strategic insights that would significantly alter the investment thesis.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The grant of restricted stock aligns management incentives with long-term shareholder value.

Negatives

• The shares are subject to forfeiture, indicating conditions must be met for full ownership.
• The vesting period extends to May 20, 2029, meaning the shares are not immediately available to the director.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed.
• The long vesting period means the shares are not liquid for the reporting person until May 20, 2029.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider stock grants, as reported in Form 4 filings, are common for executive and director compensation across the biotechnology and healthcare sectors. These grants are typically used to incentivize long-term performance and align the interests of key personnel with those of shareholders.

Stakeholder Impact

• Shareholders: The acquisition by a director, even as a grant, can be viewed positively as it aligns management interests with long-term company performance. However, the long vesting period means no immediate increase in available shares for trading by the director.
• Employees: The use of equity grants for compensation is a common practice that can motivate employees, though this specific grant is for a director.
• Management: The grant serves as a form of compensation and incentive for the director.

Next Steps

• Timothy E. Baxter must complete the requisite service period to avoid forfeiture of the restricted stock.
• The restricted stock will vest on May 20, 2029.

Key Dates

Keywords

PAVmed Inc., PAVM, Form 4, Insider Trading, Stock Grant, Restricted Stock, Director, Beneficial Ownership, Securities Exchange Act